- RecruitingPhase I
An early-stage study to see if U8:ranibizumab eye drops are safe, well-tolerated, and effective for patients with a specific eye condition called choroidal neovascularisation
This study tests new eye drops for wet AMD, a condition causing central vision loss. It checks if the drops are safe, work well, and are better than injections. We're looking for adults aged 60+ with wet AMD to join.
For: Wet age-related macular degenerationUnited Kingdom · England - Active not recruitingPHASE2, PHASE3
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
This study is looking at a new medicine, EYE103, for people with a common eye condition called diabetic macular oedema (DME). It compares EYE103 with a standard treatment, ranibizumab, to see if it's safe and helps improve vision.
For: Diabetic Macular Edema (DME)United States · Argentina · Australia - RecruitingPHASE3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
This study looks at a new way to treat a common eye condition called wet Age-related Macular Degeneration (AMD). It tests a small, refillable implant that delivers medicine directly to the eye, hoping to reduce how often people need eye injections.
For: Neovascular Age-related Macular DegenerationAustria · Czechia · Denmark - Active not recruitingPHASE3
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
This study looks at a new way to treat a common eye condition called 'wet' Age-related Macular Degeneration (nAMD). It tests how well a special eye implant works, which slowly releases medicine over a long time, compared to standard eye injections.
For: Neovascular Age-related Macular Degeneration (nAMD)Argentina · Australia · Austria